Fig. 6

Effect of free and nanocarrier delivered MTM on CSC subpopulations. A–B CSC-enriched tumourspheres of T-5 H-FC#1 cells were treated with increased concentrations of the indicated MTM formulations for 72 h. Treatments with an amount of empty nanoparticles corresponding to 10 µM (Ce) were also included. Representative images of the spheres cultures (A) and the quantification of the spheres (represented as % of control) (B) remaining at the end of experiment are shown. Scale bars = 250 μm. Error bars represent the standard deviation of at least three independent experiments. C–E Analysis of the percentage of cells presenting transcriptional activity of the pluripotency factors SOX2 and OCT4 (SORE6 activity) after the treatment with free ree MTM, MTM-NPs, MTM-LIP or MTM-HG. C–D Representative flow cytometry analysis of the SORE6 + population in untreated T5H-O-minCMV-GFP (gating control) (C) and in T5H-O-SORE6-GFP cells treated for with 20 nM MTM for the indicated times (D). C Graph showing the mean and standard deviation of three independent experiments